Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
26 10월 2023 - 5:30AM
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the
“Company”) (NASDAQ: DYAI), a global biotechnology company focused
on building innovative microbial platforms to address the growing
demand for global protein bioproduction and unmet clinical needs
for effective, affordable and accessible biopharmaceutical products
for human and animal health, and alternative proteins for food,
nutrition and wellness, today announced that it will report its
financial results for the third quarter 2023 and host a corporate
update conference call on Wednesday, November 8, 2023.
Conference Call Information
Date: Wednesday, November 8, 2023
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: 844-826-3033;
International +1-412-317-5185
Conference ID: 10183803
Webcast Link:
https://viavid.webcasts.com/starthere.jsp?ei=1593556&tp_key=ec162fd8d6.
An archive of the webcast will be available within 24 hours after
completion of the live event and will be accessible on the Investor
Relations section of the Company's website at www.dyadic.com.
To access the replay of the webcast, please follow the webcast link
above.
If you have any questions that you would like to
ask management during the Q&A session, please email
hzosiak@dyadic.com prior to the conference call.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company focused on building innovative microbial
platforms to address the growing demand for global protein
bioproduction and unmet clinical needs for effective, affordable,
and accessible biopharmaceutical products and alternative proteins
for human and animal health.
Dyadic’s gene expression and protein production
platforms are based on the highly productive and scalable
fungus Thermothelomyces heterothallica (formerly
Myceliophthora thermophila). Our lead technology, C1-cell
protein production platform, is based on an industrially proven
microorganism (named C1), which is currently used to speed
development, lower production costs, and improve performance of
biologic vaccines and drugs at flexible commercial scales for the
human and animal health markets. Dyadic has also developed the
Dapibus™ filamentous fungal based microbial protein production
platform to enable the rapid development and large-scale
manufacture of low-cost proteins, metabolites, and other biologic
products for use in non-pharmaceutical applications, such as food,
nutrition, and wellness.
With a passion to enable our partners and
collaborators to develop effective preventative and therapeutic
treatments in both developed and emerging countries, Dyadic is
building an active pipeline by advancing its proprietary microbial
platform technologies, including our lead asset DYAI-100 COVID-19
vaccine candidate, as well as other biologic vaccines, antibodies,
and other biological products.
To learn more about Dyadic and our commitment to
helping bring vaccines and other biologic products to market
faster, in greater volumes and at lower cost, please
visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
including those regarding Dyadic International’s expectations,
intentions, strategies, and beliefs pertaining to future events or
future financial performance, such as the success of and interest
in our protein production platforms, and the success of our
business development efforts. Actual events or results may differ
materially from those in the forward-looking statements because of
various important factors, including those described in the
Company’s most recent filings with the SEC. Dyadic assumes no
obligation to update publicly any such forward-looking statements,
whether because of new information, future events or otherwise. For
a more complete description of the risks that could cause our
actual results to differ from our current expectations, please see
the section entitled “Risk Factors” in Dyadic’s annual reports on
Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as
such factors may be updated from time to time in Dyadic’s periodic
filings with the SEC, which are accessible on the SEC’s website and
at www.dyadic.com.
Contact:Dyadic International,
Inc.Ping W. RawsonChief Financial OfficerPhone: (561)
743-8333Email: ir@dyadic.com
Dyadic (NASDAQ:DYAI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Dyadic (NASDAQ:DYAI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024